Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Viridian Therapeutics, Inc.\DE (VRDN)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70.8M | $302,000 | $314,000 | $1.8M | $3.0M | $1.1M | $4.5M | $8.4M | $4.0M | $3.5M | $5.7M | $6.5M | $5.5M |
| Research & development | $338.9M | $238.3M | $159.8M | $100.9M | $56.9M | $28.3M | $34.8M | $30.4M | $19.6M | $13.7M | $1.0M | $347,000 | $225,000 |
| Operating expenses | $434.2M | $299.3M | $254.8M | $136.1M | $82.7M | $111.4M | $46.4M | $41.5M | $30.5M | $20.5M | $13.7M | $11.2M | $4.5M |
| Operating income | −$363.4M | −$299.0M | −$254.4M | −$134.3M | −$79.7M | −$110.4M | −$42.0M | −$33.1M | −$26.5M | −$17.0M | −$11.2M | −$6.9M | −$197,000 |
| EBITDAderived | −$362.9M | −$298.5M | −$253.9M | −$134.0M | −$79.6M | −$110.1M | −$41.7M | −$32.8M | −$26.2M | −$16.6M | −$11.0M | −$6.7M | −$49,000 |
| Net income | −$342.6M | −$269.9M | −$237.7M | −$129.9M | −$79.4M | −$110.7M | −$41.9M | −$32.7M | −$26.5M | −$17.3M | −$11.3M | −$7.9M | −$2.2M |
| Basic EPSper diluted share | — | — | -$5.31 | -$4.05 | -$6.66 | -$31.13 | -$20.04 | -$1.10 | -$1.38 | -$28.21 | -$21.02 | -$3.50 | -$12.23 |
| Diluted EPSper diluted share | — | — | -$5.31 | -$4.05 | -$6.66 | -$31.13 | -$20.04 | -$1.10 | -$1.38 | -$28.21 | -$21.02 | -$3.50 | -$12.23 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 11, 2026Form 4 | Fairmount Healthcare Fund II L.P. +2Director,TenPercentOwner | BuyCommon Stock · indirect | 1.18M | $17.00 | $20.00M | 5.09M |
| Dec 31, 2025Form 4 | Tousignant JenniferChief Legal Officer | SellCommon Stock | 2.3K | $31.16 | $70.8K | 0 |
| Oct 23, 2025Form 4 | Fairmount Healthcare Fund II GP LLC +2Director,TenPercentOwner | BuyCommon Stock · indirect | 454.5K | $22.00 | $10.00M | 3.91M |
| Sep 27, 2024Form 4 | Beetham Thomas W.Chief Operating Officer | BuyCommon Stock | 5.0K | $23.41 | $117.0K | 6.0K |
| Sep 27, 2024Form 4 | Mahoney Stephen F.President and CEO | BuyCommon Stock | 21.4K | $23.33 | $499.3K | 21.4K |